GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Book Value per Share

Vicore Pharma Holding AB (OSTO:VICO BTA) Book Value per Share : kr89.74 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Book Value per Share?

Vicore Pharma Holding AB's book value per share for the quarter that ended in Mar. 2025 was kr89.74.

During the past 12 months, Vicore Pharma Holding AB's average Book Value Per Share Growth Rate was 2.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -2.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -7.70% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Vicore Pharma Holding AB was 41.90% per year. The lowest was -18.00% per year. And the median was -8.40% per year.

Vicore Pharma Holding AB's current price is kr8.00. Its book value per share for the quarter that ended in Mar. 2025 was kr89.74. Hence, today's PB Ratio of Vicore Pharma Holding AB is 0.09.

During the past 12 years, the highest P/B Ratio of Vicore Pharma Holding AB was 7.45. The lowest was 0.77. And the median was 2.91.


Vicore Pharma Holding AB Book Value per Share Historical Data

The historical data trend for Vicore Pharma Holding AB's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Book Value per Share Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.18 33.72 25.43 40.06 99.33

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.00 38.26 33.23 99.33 89.74

Competitive Comparison of Vicore Pharma Holding AB's Book Value per Share

For the Biotechnology subindustry, Vicore Pharma Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's PB Ratio falls into.


;
;

Vicore Pharma Holding AB Book Value per Share Calculation

Vicore Pharma Holding AB's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,129.33-0.00)/11.37
=99.33

Vicore Pharma Holding AB's Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,020.26-0.00)/11.37
=89.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Vicore Pharma Holding AB  (OSTO:VICO BTA) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Vicore Pharma Holding AB Book Value per Share Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines